{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:55:35Z","timestamp":1792108535990,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01543-7","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T02:43:53Z","timestamp":1760409833000},"page":"3793-3803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50\u00a0mg and 100\u00a0mg for Alopecia Areata"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06873945","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"McMichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Va\u00f1\u00f3-Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Woodworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshika","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feriel","family":"Robbana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Napatalung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satrajit","family":"Roychoudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"2","key":"1543_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1543_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, et\u00a0al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"1543_CR3","volume":"16","author":"FM Delamere","year":"2008","unstructured":"Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;16(2):CD004413.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1543_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/pde.15237","volume":"40","author":"S Benton","year":"2023","unstructured":"Benton S, Bellefeuille G, Rypka K, et\u00a0al. Psychosocial impact of pediatric alopecia areata: a survey study. Pediatr Dermatol. 2023;40(2):312\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1543_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556\u20138 e1.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1543_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/jpc.16678","volume":"60","author":"IJ Tan","year":"2024","unstructured":"Tan IJ, Jafferany M. Psychosocial impact of alopecia areata in paediatric and adolescent populations: a systematic review. J Paediatr Child Health. 2024;60(12):778\u201382.","journal-title":"J Paediatr Child Health"},{"issue":"5","key":"1543_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"J-P Okhovat","year":"2023","unstructured":"Okhovat J-P, Marks DH, Manatis-Lornell A, et\u00a0al. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;88(5):1040\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1543_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, et\u00a0al. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jdin.2022.05.011","volume":"8","author":"AB Kim","year":"2022","unstructured":"Kim AB, Cheng BT, Hassan S. Association of mental health outcomes and lower patient satisfaction among adults with alopecia: a cross-sectional population-based study. JAAD Int. 2022;8:82\u20138.","journal-title":"JAAD Int"},{"issue":"7","key":"1543_CR10","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/jocd.13807","volume":"20","author":"S Savas Erdogan","year":"2021","unstructured":"Savas Erdogan S, Falay Gur T, Dogan B. Anxiety and depression in pediatric patients with vitiligo and alopecia areata and their parents: a cross-sectional controlled study. J Cosmet Dermatol. 2021;20(7):2232\u20139.","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"1543_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/ijt.ijt_53_17","volume":"9","author":"ST Hussain","year":"2017","unstructured":"Hussain ST, Mostaghimi A, Barr PJ, et\u00a0al. Utilization of mental health resources and complementary and alternative therapies for alopecia areata: a U.S. survey. Int J Trichol. 2017;9(4):160\u20134.","journal-title":"Int J Trichol"},{"key":"1543_CR12","unstructured":"US Food and Drug Administration. Patient-focused drug development public meeting for alopecia areata. https:\/\/www.fda.gov\/industry\/prescription-drug-user-fee-amendments\/patient-focused-drug-development-public-meeting-alopecia-areata. Published 2018. Accessed 16 Dec 2024."},{"issue":"8","key":"1543_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/exd.14155","volume":"29","author":"M Bertolini","year":"2020","unstructured":"Bertolini M, McElwee K, Gilhar A, et\u00a0al. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703\u201325.","journal-title":"Exp Dermatol"},{"issue":"8","key":"1543_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jid.2016.04.004","volume":"136","author":"EHC Wang","year":"2016","unstructured":"Wang EHC, Yu M, Breitkopf T, et\u00a0al. Identification of autoantigen epitopes in alopecia areata. J Investig Dermatol. 2016;136(8):1617\u201326.","journal-title":"J Investig Dermatol"},{"key":"1543_CR15","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/DDDT.S172638","volume":"12","author":"K Triyangkulsri","year":"2018","unstructured":"Triyangkulsri K, Suchonwanit P. Role of Janus kinase inhibitors in the treatment of alopecia areata. Drug Des Dev Ther. 2018;12:2323\u201335.","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"1543_CR16","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/JCI31942","volume":"117","author":"A Gilhar","year":"2007","unstructured":"Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Investig. 2007;117(8):2019\u201327.","journal-title":"J Clin Investig"},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"key":"1543_CR18","doi-asserted-by":"publisher","first-page":"124556","DOI":"10.3389\/fimmu.2023.1243556","volume":"14","author":"T Passeron","year":"2023","unstructured":"Passeron T, King B, Seneschal J, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:124556.","journal-title":"Front Immunol."},{"issue":"6","key":"1543_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, et\u00a0al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342.","journal-title":"ACS Chem Biol"},{"issue":"12","key":"1543_CR20","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"JB Telliez","year":"2016","unstructured":"Telliez JB, Dowty ME, Wang L, et\u00a0al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442\u201351.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"1543_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2016","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318\u201328.","journal-title":"J Allergy Clin Immunol"},{"issue":"10387","key":"1543_CR22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et\u00a0al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"18","key":"1543_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et\u00a0al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"1543_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et\u00a0al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1543_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et\u00a0al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52\u00a0weeks of continuous therapy in two phase iii trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"key":"1543_CR26","unstructured":"King B. Deuruxolitinib demonstrates significant and continual improvement in scalp hair regrowth at 52\u00a0weeks of dosing in patients with alopecia areata: pooled efficacy results from ongoing open-label extension trials. Presented at: EADV Congress 2023. Abstract 6743."},{"issue":"3","key":"1543_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40262-024-01347-6","volume":"63","author":"Y Huh","year":"2024","unstructured":"Huh Y, Wojciechowski J, Purohit VS. Moving beyond boundaries: utilization of longitudinal exposure-response model for bounded outcome score to inform decision making in the accelerated drug development paradigm. Clin Pharmacokinet. 2024;63(3):381\u201394.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1543_CR28","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/art.41316","volume":"72","author":"MF Robinson","year":"2020","unstructured":"Robinson MF, Damjanov N, Stamenkovic B, et\u00a0al. Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020;72(10):1621\u201331.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1543_CR29","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","volume":"21","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, et\u00a0al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023;21(10):2616\u201328.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1543_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/art.43184","author":"SI Danto","year":"2025","unstructured":"Danto SI, Salganik M, Banerjee A, et al. Efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43184.","journal-title":"Arthritis Rheumatol"},{"key":"1543_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/CLEP.S242097","volume":"12","author":"K Thorlund","year":"2020","unstructured":"Thorlund K, Dron L, Park JJH, Mills EJ. Synthetic and external controls in clinical trials\u2014a primer for researchers. Clin Epidemiol. 2020;12:457\u201367.","journal-title":"Clin Epidemiol"},{"key":"1543_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20547","author":"B King","year":"2025","unstructured":"King B, Mirmirani P, Lo Sicco K, et\u00a0al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20547.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1543_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, et\u00a0al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1543_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1204","volume":"12","author":"S Anderson","year":"2024","unstructured":"Anderson S, Cavaletti G, Hood LJ, et\u00a0al. A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata. Pharmacol Res Perspect. 2024;12(4):e1204.","journal-title":"Pharmacol Res Perspect"},{"key":"1543_CR35","first-page":"530","volume":"2023","author":"N Neehal","year":"2023","unstructured":"Neehal N, Anand V, Bennett KP. Framework for research in equitable synthetic control arms. AMIA Annu Symp Proc. 2023;2023:530\u20139.","journal-title":"AMIA Annu Symp Proc"},{"key":"1543_CR36","unstructured":"US Food and Drug Administration. Submitting documents using real-world data and real-world evidence to FDA for drug and biological products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products. Published 2022. Accessed 16 Dec 2024."},{"key":"1543_CR37","unstructured":"European Medicines Agency. Clinical trials in small populations\u2014scientific guideline. https:\/\/www.ema.europa.eu\/en\/clinical-trials-small-populations-scientific-guideline. Published 2007. Accessed 16 Dec 2024."},{"key":"1543_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jclinepi.2018.09.003","volume":"105","author":"M Anderson","year":"2019","unstructured":"Anderson M, Naci H, Morrison D, et\u00a0al. A review of NICE appraisals of pharmaceuticals 2000\u20132016 found variation in establishing comparative clinical effectiveness. J Clin Epidemiol. 2019;105:50\u20139.","journal-title":"J Clin Epidemiol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01543-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:14Z","timestamp":1763198534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01543-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01543-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brett King has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator and\/or is on a data monitoring committee for AbbVie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Arena Pharmaceuticals, Aslan Pharmaceuticals, Bristol Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, GSK, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka\/Visterra Inc, Pfizer Inc, Q32 Bio Inc, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc, and Ventyx Biosciences Inc. He has served on speakers bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. Amy McMichael has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator for Arcutis, Almirall, AbbVie, Bristol Meyers Squibb, Concert, Eli Lilly, Galderma, Incyte, Janssen, Johnson & Johnson, Kenvue, L\u2019Oreal, Leo, Pelage, Pfizer, Procter & Gamble, Revian, Sanofi Regeneron, Sun Pharma, and UCB. Rodney Sinclair has provided professional services to Aerotech, AbbVie, AstraZeneca, Akesobio, Amgen, Arcutis, Arena, Ascend, Bayer, BMS, Boehringer Ingelheim, Celgene, Coherus BioSciences, Connect, Cutanea, Demira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, MedImmune, Merck, MSD, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone, Roche, Samson Clinical, Sanofi, Sun Pharma, and UCB. Sergio Va\u00f1\u00f3-Galvan reports consulting fees and payment\/honoraria from Pfizer and Eli Lilly. Robert Wolk, Deborah Woodworth, Koshika Soma, Feriel Robbana, Alexandre Lejeune, Lynne Napatalung, Ernest Law, Dalia Wajsbrot, Cunshan Wang, and Satrajit Roychoudhury are employees of and own stock in Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study will be conducted in accordance with the protocol and with the consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and CIOMS International Ethical Guidelines; applicable International Council for Harmonisation Good Clinical Practice guidelines; and applicable regional laws and regulations, including privacy laws. The protocol, protocol amendments, and other relevant documents are reviewed and approved by the sponsor and submitted by the investigator for review and approval by the institutional review board\/ethics committee before the study can be initiated. All participants or their legally authorized representative must provide written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}